For over 15 years, Dr Anthony Shum, a pulmonologist at the University of California, San Francisco has been studying a rare genetic disorder called the COPA Syndrome. It stands for coatomer subunit alpha and is a rare, inherited disorder that affects the lungs, joint, and kidney. The National Organization for Rare Disorder also notes that it is a genetic autoimmune disorder that is caused by mutations in the COPA gene. This disease affects families unpredictably—some individuals with the mutation develop severe lung damage early in life, while others remain completely healthy. Now, Shum’s team has discovered a protective genetic variant that may offer new hope for treatment.

A Breakthrough

Researchers found that some relatives of COPA Syndrome patients stayed healthy despite carrying the same COPA gene mutation that causes the disease. The key difference? These unaffected individuals had a protective version of another gene called HAQ-STING.

When scientists introduced HAQ-STING into diseased lung cells from COPA patients, the cells returned to a balanced state, suggesting that this gene could be used as a therapy.

“We really think HAQ-STING could be a gene therapy tool and a step toward a cure,” said Shum, whose findings were published in the Journal of Experimental Medicine.

Families Who Solved The Mystery

Shum’s journey into COPA Syndrome research began in 2011 when he treated a young woman, Letasha, who had severe lung bleeding. Her mother, Betty Towe, mentioned that Letasha’s sister, Kristina, had suffered from similar symptoms. Over the years, Betty had taken both daughters on a four-hour trip to UCSF for treatment. After tracing their family history, Shum discovered that their distant relatives in Texas and Oakland also had lung problems and arthritis. In 2015, Shum, along with scientists from Baylor College of Medicine and Texas Children’s Hospital identified the COPA gene mutation. They realized that it was the common factor behind the illness. However, only some of the 30 individuals with the mutation actually developed symptoms, leaving a major question unanswered.

The Domino Effect

It was established that it occurs when a mutated COPA gene causes another gene STING to go overdrive. The STING that helps fight infections in COPA patients, remain permanently active, which leads to chronic inflammation that damages the lungs, kidneys, and joints. In 2020, while studying STING’s role in the disease, researchers discovered a key variation: HAQ-STING. This version of STING, present in about one-third of the population, appeared to neutralize the harmful effects of the COPA mutation.

To confirm their theory, the scientists needed both affected and unaffected family members to participate in the testing. Letasha, Kristina and Betty immediately volunteered. The researchers then analyzed DNA samples from 26 COPA patients and their healthy relatives. They also conducted CT scans and blood tests to ensure that unaffected members did not have any hidden symptoms. When the findings were all clear, it was revealed that all the healthy individuals had HAQ-STING, while none of the COPA patients did. This was the first known case of a common gene variant completely protecting against a severe genetic disease.

Encouraged by this discovery, researchers tested HAQ-STING’s effects in a lab setting. They introduced it into diseased lung cells from COPA patients, and the cells returned to normal function.

Way Ahead

Shum believes HAQ-STING could lead to game-changing treatments, including:

• Prenatal gene therapy for babies diagnosed with COPA Syndrome before birth
• Aerosol delivery of HAQ-STING for adults, directly targeting the lungs

Before publishing their findings, Shum called Betty with the news—her own HAQ-STING gene had protected her from the disease. He also informed Letasha and Kristina, who were overwhelmed with relief and joy.

“We always believed Dr. Shum would get to the bottom of it,” said Letasha. “This discovery is going to change lives.”

In a global first, India's drug regulator has approved a fully synthetic cannabidiol (CBD) therapy for the treatment of mild to moderate anxiety disorders, marking a significant milestone in cannabinoid-based medicine.

The Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to Zenara Pharma, the manufacturing partner of Leiutis Pharmaceuticals, to produce a synthetic cannabidiol oral solution (150 mg/ml). The prescription-only therapy is intended to be used alongside cognitive behavioural therapy (CBT) for managing mild to moderate anxiety disorders.

In a statement, Leiutis Pharmaceuticals said the approval follows a successful Phase III clinical trial conducted in India under CDSCO guidelines. A Phase IV post-marketing study will now be carried out to further evaluate the therapy.

World's First Fully Synthetic CBD Therapy

Leiutis noted that "this is the first regulatory approval anywhere in the world for a fully synthetic cannabidiol oral solution for anxiety disorders".

K. Chandrasekhar, CEO and Managing Partner of Leiutis Pharmaceuticals LLP, said the approval is the result of nearly a decade of cannabinoid research, including the development of a proprietary synthetic cannabinoid manufacturing process, novel drug-delivery technology, and extensive preclinical and clinical studies.

“Developed entirely in India and protected by patents in key markets, this approval is a significant milestone for our innovation pipeline, paving the way for next-generation cannabinoids. We thank the Government of India, clinical investigators, researchers and study participants who made it possible,” Chandrasekhar said.

What Is the New CBD Therapy?

The newly approved medicine contains a fully synthetic cannabidiol (CBD) active pharmaceutical ingredient (API), meaning no cannabis plant material is used in its production.

The therapy combines:

• A synthetic cannabidiol API developed by Biophore India Pharmaceuticals.
• Leiutis Pharmaceuticals' proprietary nanodispersible drug-delivery platform to improve absorption.
• Manufacturing by Zenara Pharma at facilities compliant with CDSCO, US FDA and European regulatory standards.

Biophore has also filed a United States Drug Master File (US DMF) for the synthetic CBD manufacturing process, reflecting internationally recognized quality standards.

Why This Approval Matters

The approval comes at a time when anxiety disorders are rising sharply in India. According to a recent analysis from the Global Burden of Disease Study published in The Lancet, anxiety disorders in India increased by 123.5% between 1990 and 2023.

The prevalence rose from 2,591.9 cases per lakh population in 1990 to 5,792.8 cases per lakh in 2023, driven largely by increasing rates of anxiety and depression.

What Is CBD?

Cannabidiol (CBD) is one of the naturally occurring compounds found in hemp and cannabis plants. Unlike THC, it does not produce intoxicating effects.

CBD has been studied for several potential therapeutic uses, including:

• Reducing anxiety symptoms
• Relieving chronic pain
• Improving sleep
• Managing certain seizure disorders
• Reducing inflammation

The newly approved product, however, uses synthetic CBD, which is produced entirely in a laboratory rather than extracted from the cannabis plant. Synthetic CBD offers a highly consistent and contaminant-free formulation, helping standardize dosing and quality.

Does CBD Have Proven Medical Benefits?

CBD already has established medical use in certain seizure disorders in some countries and continues to be investigated for a range of other conditions, including anxiety, chronic pain, inflammation and schizophrenia.

CBD is generally well-tolerated, but some users may experience mild side effects like drowsiness, reduced appetite, or diarrhea. Side effects are often due to interactions with other medications.

For many women, the last day of treatment feels like crossing a finish line they have been running toward for months. There is relief, there is gratitude, and there is often a quiet sense of disbelief that it is actually behind them. But finishing treatment is not really the end of the journey. It is the start of a new chapter—one we call survivorship—and it deserves just as much care and attention as everything that came before. Understanding what lies ahead can make all the difference between living in fear and living well.

Follow-Up Care Must Continue

Recovery does not mean walking away from the hospital. In the first few years after treatment, survivors are usually asked to return for follow-ups. The reason behind this is simple: if cancer ever returns, catching it early gives the best chance of treating it successfully. Or in many cases it a good habit to keep a check and boost confidence to the survivors.

Impact of treatment

What often surprises many women is that the impact of cancer treatment may continue even after active treatment ends. Recovery is a gradual process, and experiences can vary significantly from one individual to another depending on the type of cancer, treatment approach, and overall health. In terms of breast cancer, some women may continue to face physical, emotional, or lifestyle-related challenges during survivorship, while others may require ongoing therapies or follow-up care to reduce the risk of recurrence. What must always be remembered is that these issues cannot be addressed in silence. Open communication between the woman and her treatment team may allow problems to be sorted out in time, with the proper support being provided.

Emotional Health Deserves Equal Attention

Healing is not only physical. Many survivors carry a constant worry about whether the cancer will come back, while others feel strangely lost once the busy routine of treatment falls away. These emotions are completely natural and nothing to be ashamed of. Speaking to a counsellor, joining a support group, or simply being honest with the care team can lighten the burden enormously.

Healthy Habits Support Recovery

The choices made every day genuinely shape long-term health. Eating plenty of vegetables, fruits, and whole grains, and staying active with something as simple as a thirty-minute walk most days, makes a real difference. Keeping to a healthy weight is especially important, because carrying excess weight is linked to a higher chance of the cancer returningi. Cutting back on alcohol and staying away from tobacco add further protection.

Adjusting to Physical Changes

The body changes after cancer and coming to terms with this takes time. Worries about appearance and intimacy are entirely understandable, and they are worth raising during clinic visits, because often there are practical ways to help.

Be an Informed Advocate

No one understands a patient's body better than the patient herself, which is why every survivor should feel empowered to ask questions. Before treatment ends, it is wise to request a survivorship care plan. This is a summary of the treatment received, together with a clear schedule for future check-ups. Such a document becomes an invaluable guide, both for the survivor and for any doctor she may see in the years ahead.

Looking Ahead

Survivorship is rarely a straight line. There will be good days and harder ones, moments of confidence and moments of doubt. With regular check-ups, a few sensible habits, and the support of people who care, life after breast cancer can be every bit as rich and full as before—sometimes even more so. Because in the end, the goal of cancer treatment was never just to help women survive. It was always to help them truly live.

More than 57 million people worldwide are living with dementia, a number expected to triple to over 152 million by 2050. While there is still no cure, growing evidence suggests that healthy lifestyle changes can help improve brain health and preserve cognitive function in older adults at risk of dementia.

A major study published in The Lancet suggests that adopting healthy lifestyle habits can significantly improve memory and thinking skills in older adults at risk of dementia.

The study found that a culturally adapted, structured lifestyle program delivered across 11 Latin American countries produced meaningful improvements in cognitive function over two years. Participants in the intensive program showed 55 per cent greater improvement in overall cognition than those who received general health advice.

Lead author Lucia Crivelli, principal investigator at Fleni, a neurological institute in Buenos Aires, Argentina, said culturally adapted lifestyle interventions can be successfully implemented across diverse communities and "deliver cognitive benefits" for people at risk of dementia.

"Addressing multiple lifestyle factors can positively impact brain health and may eventually be combined with emerging drug therapies to reduce cognitive decline and dementia risk," added Heather M. Snyder, senior vice president of medical and scientific relations at the Alzheimer's Association.

What Did The Study Find?

Also read: Osteoporosis Affects Nearly 20% Of US Women Aged 50+: Why Screening Is Key

The clinical trial enrolled 1,065 adults aged 60 to 77 years at increased risk of cognitive decline across 12 sites in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, Mexico, Peru and Uruguay.

Participants were randomly assigned to one of two groups. The Systematic Lifestyle Intervention (SLI) group received ongoing coaching, supervised exercise, personalized nutrition counselling, cognitive training and regular monitoring of cardiovascular risk factors. The Flexible Lifestyle Intervention (FLI) group received general lifestyle recommendations through periodic health education sessions without continuous coaching or supervision.

The structured program combined supervised exercise, a brain-healthy MIND diet, computer-based cognitive training, regular monitoring of blood pressure, blood sugar and weight, and social engagement activities designed to encourage accountability and interaction.

To improve participation, the intervention was adapted to local cultures. Exercise sessions incorporated familiar activities such as salsa and tango, while nutrition counselling focused on regionally available foods including avocado, quinoa, açaí, chia seeds, pumpkin seeds and aguaymanto.

Read More: Study Decodes Why COVID Survivors Continue To Suffer Vision Problems

After two years, participants in the structured intervention experienced:

• 55 per cent greater improvement in overall cognitive performance than those in the flexible intervention group.

• The largest gains in memory.

• Significant improvements in executive function, including planning and decision-making.

• Faster processing speed.

The cognitive benefits were consistent regardless of participants' age, education level, ethnicity or genetic risk for Alzheimer's disease.

The authors noted that while the program improved performance on cognitive tests, it did not determine whether the intervention prevents dementia. They said longer-term follow-up is needed to establish whether these cognitive improvements ultimately reduce the risk of developing the disease.

What Is Dementia?

Dementia is an umbrella term used to describe a significant decline in mental function that is serious enough to affect everyday life. It commonly impacts memory, thinking, and reasoning skills. Dementia itself is not a single disease but a collection of symptoms caused by underlying conditions such as Alzheimer’s disease or vascular dementia.

Common signs include

• memory problems,
• confusion,
• difficulty finding words,
• changes in mood or behavior,
• trouble completing familiar tasks.